Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3384-3387

  England, Kathleen ^a   Boshoff, Helena I M ^a   Arora, Kriti ^a   Weiner, Danielle ^a   Dayao, Emmanuel ^a   Schimel, Daniel ^a   Via, Laura E ^a   Barry III, Clifton E ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CARBAPENEM; CILASTATIN; CLAVULANIC ACID; DORIPENEM; ERTAPENEM; FROPENEM; IMIPENEM; ISONIAZID; MEROPENEM; RIFAMPICIN;

ADD ON THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG STABILITY; DRUG TOLERABILITY; IN VIVO STUDY; LUNG; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIMATE; PRIORITY JOURNAL; SPLEEN; TREATMENT OUTCOME; TUBERCULOSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; CELL LINE; CLAVULANIC ACID; DRUG THERAPY, COMBINATION; MACROPHAGES; MICE; MYCOBACTERIUM TUBERCULOSIS; THIENAMYCINS;

EID: 84861146540     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05690-11     Document Type: Article

References (20)

1. Baldwin CM, Lyseng-Williamson KA, Keam SJ. 2008. Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs 68:803-838. (Pubitemid 351559562)
2. Bax RP, et al. 1989. The pharmacokinetics of meropenem in volunteers. J. Antimicrob. Chemother. 24(Suppl A):311-320. (Pubitemid 19248752)
3. Cuffini AM, et al. 1993. The entry of meropenem into human macrophages and its immunomodulating activity. J. Antimicrob. Chemother. 32:695-703. (Pubitemid 23343753)
4. Edwards JR. 1995. Meropenem: a microbiological overview. J. Antimicrob. Chemother. 36(Suppl A):1-17.
5. Finlay J, Miller L, Poupard JA. 2003. A review of the antimicrobial activity of clavulanate. J. Antimicrob. Chemother. 52:18-23. (Pubitemid 36850079)
6. Fukasawa M, et al. 1992. Stability of meropenem and effect of 1β-methyl substitution on its stability in the presence of renal dehydropeptidase I. Antimicrob. Agents Chemother. 36:1577-1579.
7. Harrison MP, et al. 1989. The disposition and metabolism of meropenem in laboratory animals and man. J. Antimicrob. Chemother. 24(Suppl A):265-277. (Pubitemid 19248748)
8. Hugonnet JE, Blanchard JS. 2007. Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate. Biochemistry 46:11998-12004. (Pubitemid 350022357)
9. Hugonnet JE, Tremblay LW, Boshoff HI, Barry CE III, Blanchard JS. 2009. Meropenem-clavulanate is effective against extensively drugresistant Mycobacterium tuberculosis. Science 323:1215-1218.
10. Mendez AS, Dalomo J, Steppe M, Schapoval EE. 2006. Stability and degradation kinetics of meropenem in powder for injection and reconstituted sample. J. Pharm. Biomed. Anal. 41:1363-1366. (Pubitemid 43775879)
11. Nicolau DP. 2008. Carbapenems: a potent class of antibiotics. Expert Opin. Pharmacother. 9:23-37. (Pubitemid 351233746)
12. Takeuchi Y, Sunagawa M, Isobe Y, Hamazume Y, Noguchi T. 1995. Stability of a 1 beta-methylcarbapenem antibiotic, meropenem (SM-7338) in aqueous solution. Chem. Pharm. Bull. (Tokyo) 43:689-692.
13. Topham JC, Murgatroyd LB, Jones DV, Goonetilleke UR, Wright J. 1989. Safety evaluation of meropenem in animals: studies on the kidney. J. Antimicrob. Chemother. 24(Suppl A):287-306. (Pubitemid 19248750)
14. Tremblay LW, Hugonnet JE, Blanchard JS. 2008. Structure of the covalent adduct formed between Mycobacterium tuberculosis beta-lactamase and clavulanate. Biochemistry 47:5312-5316. (Pubitemid 351656975)
15. Tsenova L, et al. 2005. Virulence of selected Mycobacterium tuberculosis clinical isolates in the rabbit model of meningitis is dependent on phenolic glycolipid produced by the bacilli. J. Infect. Dis. 192:98-106. (Pubitemid 40863862)
16. Via LE, et al. 2008. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect. Immun. 76:2333-2340.
17. Viaene E, Chanteux H, Servais H, Mingeot-Leclercq MP, Tulkens PM. 2002. Comparative stability studies of antipseudomonal betalactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob. Agents Chemother. 46:2327-2332. (Pubitemid 34793431)
18. Wang F, Cassidy C, Sacchettini JC. 2006. Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics. Antimicrob. Agents Chemother. 50:2762-2771. (Pubitemid 44198699)
19. WHO. 2010. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. World Health Organization, Geneva, Switzerland.
20. Wiseman LR, Wagstaff AJ, Brogden RN, Bryson HM. 1995. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 50:73-101.